Skip to Main Content
Go to Why Work Here page
Putnam Associates logo

Putnam Associates
Related Internships: 
Putnam Associates Internship Program


At a Glance


“The people at the firm are its biggest asset.”

“Interesting, challenging, and impactful projects.”

“Low-travel model.”


“Occasional crunch time.”

“Deadlines and tough clients.”

“Hierarchy can be vague.”

The Buzz

“Competitive in health and life sciences.”

“Venerable consulting outfit.”

“Great at quantitative market research.”

About Putnam Associates

For more than 30 years, Putnam Associates has grown into a premier strategy consulting firm serving biopharmaceutical, biotechnology (cell, gene and tissue therapies), diagnostics, medical device, and related clients in the healthcare space. The firm provides objective, high impact strategic advice and analytical services, helping to support clients in crucial business decisions at all stages of the product and franchise lifecycle. Putnam's clients range from venture-backed biotechs to fortune 500 companies, including the majority of the world's major biopharmaceutical companies–indeed, despite being based in the US, more than half of Putnam's projects are global in focus. Putnam's commitment to client success has sustained many relationships that stretch back more than a decade and has enabled continued expansion into new client opportunities every year.

Product evolution

Putnam focuses solely on the life sciences, offering services focused on both development-stage and marketed products. That's good news for clients, who can spend more than 10 years developing new products–including wading through years of discovery, comprehensive testing, regulatory reviews, and commercialization prep–before the products even make it to market. Services fall into five main areas: Pricing and Market Access, New Product Development Strategy, Commercialized Product and Franchise Strategy, Portfolio and Business Development Strategy, and Enterprise Solutions.

Committed to Long-Term Relationships

By providing insight and long-term support, Putnam has become the strategic partner of choice to a growing roster of clients. That long-term commitment also goes for the firm's employees–rather than being a landing spot for a year or two, the firm wants employees to see the potential for a longer-term career at Putnam. The firm provides both formal and informal mentorship, and cultivates an enriching professional culture. Knowledge development projects delve into the latest breakthroughs in areas like cell, gene, and tissue therapy leading to exciting new clients. The firm promotes community engagement and personal growth. Putnam sponsors a Summer Days of Service initiative driven by staff where Putnam teams volunteer their time and energy to support Boston and San Francisco area community organizations.

When Putnam's consultants do leave, the firm is committed to fostering the professional success of alumni, recently launching a program of alumni outreach and events that bring together a growing roster of former staff that have gone on to success in other biotech pursuits.

Ensuring a Successful Launch

Nearly half of Putnam's projects in the past year have addressed the challenges of bringing cutting edge medical innovations to market. The firm is currently supporting clients on the cutting edge in CAR-T cancer therapies, gene therapies, and stem cell therapies. In a typical recent project, Putnam helped validate the epidemiology of untreated patient populations, then worked with the client to better define unmet medical needs in the therapeutic area. This led to recommendations around endpoints in Phase III trial designs. Putnam then worked with the commercial team to build strategies around introducing the product to target markets. At the same time, Putnam helped build forecast models for key countries and conducted pipeline assessments to help the client keep abreast of fast-moving clinical developments among competitors (which also informed in-licensing scans). Whether Putnam's clients are honing their portfolios, developing new products, or trying to grow marketed products, the firm's strength lies in its ability to consistently deliver exceptional work and superior insights on the industry's complex challenges.

In the News

Benjamin Diop Promoted to Partner

JULY 11, 2019

Putnam is pleased to announce the promotion of Benjamin Diop to Partner.

“Benjamin is the rare talent that brings a deep technical background, a sharp strategic perspective, and a true partnership attitude to all of his engagements.  His commitment to his client’s success is second to none.  He has helped his clients navigate some of the most complex and fast-evolving markets in the life sciences industry and in doing so has helped drive the outstanding growth of our firm,” said Matt Riordan, Partner at Putnam Associates.  “Everyone here at Putnam knows Benjamin is never without a smile and today we are all smiling as we announce his promotion to Partner.  We look forward to his future success with the firm.”

Benjamin serves a range of life-science companies developing market opportunity assessments, global pricing and market access, therapeutic area, franchise, and product growth strategy, detailed forecasting, and market modeling.  Benjamin has particular experience leading projects in oncology where he has mainly focused on both hematologic disorders (CML, MF, MM) and solid tumors (Pancreatic, Lung, Breast, and Glioblastoma), cardiovascular diseases, and infectious diseases. He also has broad experience leading cases involving launch preparation, launch planning, and the associated development of a value story and access landscape. Prior to joining Putnam, Benjamin was a Life Science specialist at L.E.K. Consulting with a focus on the healthcare, pharmaceuticals, and med-tech industries. He received a Ph.D. from the joint Harvard – MIT Division of Health Sciences and Technology. Benjamin’s Ph.D. research focused on drug delivery in tumors. Benjamin also received a B.Eng in Chemical Engineering from Vanderbilt University.

Ryan Wyrtzen Promoted to Partner

JULY 11, 2019

Putnam is pleased to announce the promotion of Ryan Wyrtzen to Partner.

“Promoting someone to partner is always special; however, when it is someone that joined Putnam straight out of undergraduate and worked themselves up to partner it is extra rewarding,” said Remco op den Kelder, CEO at Putnam Associates.  “I can’t say enough about the value that Ryan has provided not only to our clients; however, to the countless individuals that he has mentored over the years. Having worked closely with Ryan over the years I could not be more proud of him, I know we will be doing great things over the coming years.”

Ryan serves leading biopharmaceutical and early-stage life-science companies in strategic areas related to commercial opportunity assessment, pricing and market access strategy, and strategic marketing at the franchise and product level.  He has broad experience working across client functional groups including marketing, finance, and medical affairs, across geographies with his extensive work in the EU, US, and emerging markets, and across therapeutic areas, including vaccines, oncology, rheumatology, cardiology, and neurology. He has a sterling track record of helping clients achieve impactful results. Prior to joining Putnam, Ryan worked at the Health Connector, the Massachusetts state health insurance exchange. Originally from Massachusetts, Ryan earned an MBA from Harvard Business School and a BA in Economics and History from Brown University, where he graduated magna cum laude and was elected to Phi Beta Kappa.

Putnam Holds Annual Advanced Consulting Skills Training at Wentworth by the Sea

APRIL 09, 2019

Putnam held its annual Advanced Consulting Skills Training at Wentworth by the Sea in New Castle, NH.  The program has grown to 40 participants and is for Associate Consultants and Life Sciences Consultants who are evolving toward managerial roles.  The training includes mastering qualitative research, optimizing case-team operations, and developing compelling presentations and recommendations.

The 2-day program also provides an opportunity for participants to connect, have fun, and get to know each other outside the office.  After the first day of training, the group participated in a brewery tour through Granite State Growler Tours of local breweries including Tributary, Woodland Farms, Liar’s Bench and Loaded Question followed by dinner at Martingale Wharf in downtown Portsmouth. The training complements our New-Employee Introductory Training and our Case Team Leadership Symposium, both held every fall, to ensure that colleagues at all levels get opportunities to learn new skills, examine new challenges that accompany role growth, and consider how to improve our methodologies and execution.

Eric Auger Participates in Guggenheim Healthcare Talks Panel on Innovative Payment Models for Gene Therapy

APRIL 4, 2019

Eric Auger, Partner, was an expert panelist at the Guggenheim Healthcare Talks Rare Disease and Genomic Medicines Day in Cambridge, Massachusetts.  The session was titled “Gene Therapy Pricing: Challenges to Innovative Payment Models and Potential Solutions”.  Based upon his work with pioneering gene- and cell-therapy companies, Eric was invited to discuss the market access and payment model issues that gene-therapy companies face, experiences of pioneering products and companies, and considerations for pricing and payment model innovation as the sector grows.  In addition to Eric, Joshua Cohen, formerly at Tufts Center for the Study of Drug Development participated on the panel.

The session was hosted by Whitney Ijem and Michael Schmidt of Guggenheim Partners.

Putnam Proudly Supports the MIT Solve Pi Day Micro-Challenge

MARCH 13, 2019

In honor of PiDay (3/14), SolveMIT teamed up with the MIT 24-Hour Challenge Pi Day 2019. The challenge:  If 6,283 MIT alumni, students, parents, and friends gave to MIT on March 14, 2019, a generous anonymous alum challenger would give the Institute $314,159, fueling the future at MIT and around the world. By giving to Solve this Pi Day, donors would open the doors of a world-class institution to entrepreneurs from all corners of the world who represent the spirit of MIT.

As part of the micro- challenge, Solve members Putnam Associates, Red Carpet Capital Limited UK, and Kevin Xu made a generous donation of $15,000 to MIT Solve!

MIT Solve is a marketplace for social impact. They find tech entrepreneurs from around the world and broker partnerships across the community to scale their innovative work—driving lasting, transformational change.  Solve issues four Challenges each year to find the most promising Solver teams with solutions to the world’s most pressing problems. Solve then deploys its global community of private, public, and nonprofit leaders to form the partnerships these Solver teams need to scale their impact. Over the last two years, Solve and its partners have committed over US $7 million to 99 incredible Solver teams developing technology-driven solutions to the world’s most pressing problems. Putnam is a proud member of the SOLVE community.  In the spirit of MIT’s 24-Hour Challenge, we invite you to pledge your support for Solve’s programs by donating online.  

Domenick Bertelli Chairs Biopharma Digital Adoption Panel at the MIT Sloan Healthcare and BioInnovations Conference

FEBRUARY 21, 2019

Domenick chaired the Biopharma Digital Adoption Panel at the 17th Annual MIT Sloan Healthcare and BioInnovations Conference (SHBC).  The Panel focused on exploring how the life sciences industry is adopting new technologies and approaches enabled by digital advances across the biopharma value chain, from Discovery to the clinic to the marketplace.  The discussion covered topics including:

  • How AI and next-generation lab equipment are reshaping drug discovery and identification of biomarkers
  • How digital technologies are enabling new approaches to clinical trial design (stratification, end points), patient recruitment, outcome analysis, and post-trial follow-up
  • How new digital platforms are enabling more effective outreach to patients and physicians

Panelists included:

  • Rob Goodwin, Vice President and Head of Global Product Development Operations Center of Excellence, Pfizer
  • Jeremy Jenkins, PhD, Executive Director and Head of Data Science in Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research
  • Eduardo Cornejo, ITS Digital Innovation Market Lead, Sanofi
  • Jennifer Staffin, Automation Solutions Leader, GE Healthcare Life Sciences
  • Noam Kirson, PhD, Managing Principal, Analysis Group

The MIT Sloan Healthcare and BioInnovations Conference brings together industry, academic and policy leaders to discuss the most pressing issues and exciting innovations in the healthcare sector. The theme of this year’s conference was “Frontiers in the Digital Era: Decoding the Future of Healthcare”.  Putnam was proud to once again be a sponsor and co-organizer of the SHBC conference.

Why Work Here

Why Putnam?

  • At Putnam, we operate with a team-based approach that is client focused and impact oriented.
  • Putnam is a specialist firm where employees are given the opportunity to excel.
  • Putnam relies on the talent and motivation of our staff.
  • Putnam Associates has built a close-knit and supportive culture.

Putnam Associates

501 Boylston Street
Boston, MA 02116
Phone: (617) 456-5200

Firm Stats

Employer Type: Private
CEO: Remco op den Kelder
2019 Employees (All Locations): 125

Major Office Locations

Boston, MA (HQ)
San Francisco, CA

Major Departments & Practices

Pricing and Market Access

New Product Development Strategy

Commercialized Product and Franchise Strategy

Portfolio and Business Development Strategy

Enterprise Solutions